Vasca defends LifeSite device as lawsuit filed
This article was originally published in Clinica
Vasca, which has developed the LifeSite haemodialysis access system, has said it plans to strenuously defend against claims raised in a lawsuit filed in California on behalf of a patient. The claims relate to the company's sale of the product as well as issues raised in an FDA warning letter sent in November 2001, the Tewksbury, Massachusetts-based company said. Since the device went on sale, the letter states, there have been at least 129 complaints reported to the company involving death or serious injury.
You may also be interested in...
The first trial of the new Flash ultra-high dose radiation therapy with Varian Medical Systems’ ProBeam particle accelerator has begun. Agum Sharda, Varian’s senior director of Flash, says the technology could be a major advance for cancer patients.
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.